vTv Therapeutics (VTVT) Net Margin (2014 - 2026)

vTv Therapeutics has disclosed Net Margin across 11 years of filings, most recently posting 65.51% for Q1 2026.

• Net Margin for Q1 2026 came in at 65.51%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 6.11% (up 10994141.0% YoY), and the FY2024 annual result was 1815.34%, changed N/A from the prior year.
• Net Margin came in at 65.51% for Q1 2026 at vTv Therapeutics, up from 21376.47% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 65.51% in Q1 2026 to a low of 52722.22% in Q4 2022.
• The 3-year median for Net Margin is 10931.49% (2024), against an average of 18313.52%.
• Peak annual rise in Net Margin reached 2562222 bps in 2022, while the deepest fall reached 2825556 bps in 2022.
• vTv Therapeutics' Net Margin stood at 52722.22% in 2022, then surged by 59 bps to 21376.47% in 2024, then jumped by 100 bps to 65.51% in 2026.
• The last three Net Margin figures came in at 65.51% (Q1 2026), 21376.47% (Q4 2024), and 486.5% (Q1 2024), per Business Quant data.